Horizon's Tepezza Broke The Mold For 2020 Launches, But Still Got Snared By COVID-19
An Interview With CEO Tim Walbert
Executive Summary
Tepezza was the breakout launch of the year and will change Horizon's growth trajectory, but for now it has been sidelined by a supply constraint caused by COVID-19 vaccine manufacturing.
You may also be interested in...
Horizon Headed For A Breakout Year As Tepezza Relaunch Exceeds Goals
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.
S&E Briefs: The Good and The Bad Of COVID-19 On Biotech's Top Line
Regeneron's COVID-19 antibody cocktail helped drive 38% growth for the company, while Global Blood Therapeutics' Oxbryta continues to face headwinds and Horizon focuses on relaunches.
With Return Of Tepezza Supply, Horizon Is Ready To Get Back To Business
US FDA approved new manufacturing for Tepezza, which had been sidelined by COVID-19 vaccine production. Horizon said it will resupply the market in April.